Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03

Tissue Antigens

Volumn 70, Issue 4, 2007, Pages 283-293

  Bhattacharya, P ^a   Sengupta, S ^a  

^a INDIAN STATISTICAL INSTITUTE   (India)

Author keywords

Cervical cancer; HLA B*07 allele; HLA DQB1*03 homozygosity; Host genetic factors; HPV16 18 infections; p53 codon 72 polymorphism

Indexed keywords

HLA B ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL TRANSFORMATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEREDITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENETICS; INDIAN; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HLA-B ANTIGENS; HLA-DQ ANTIGENS; HOMOZYGOTE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INDIA; LOGISTIC MODELS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROLINE; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 34548346853     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2007.00894.x     Document Type: Article

References (31)

1. Walboomers JMM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive CaCx worldwide. J Pathol 1999 : 189 : 12 9.
2. Meleif CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992 : 58 : 143 75.
3. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991 : 49 : 281 355.
4. Hildesheim A, Schiffman M, Scott DR et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998 : 7 : 1035 41.
5. Wang SS, Wheeler CM, Hildesheim A et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001 : 184 : 1310 4.
6. Bhattacharya P, Sengupta S. HLA DQB1*03 genotypes and susceptibility to cervical cancer in Indian women. Int J Hum Genet 2005 : 5 : 19 25.
7. Bhattacharya P, Duttagupta C, Sengupta S. Proline homozygosity in codon 72 of p53: a risk genotype for human papillomavirus related cervical cancer in Indian women. Cancer Lett 2002 : 188 : 207 11.
8. Bhattacharya P, Sengupta S. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21 jointly mediate cervical cancer susceptibility among Indian women. Gynecol Oncol 2005 : 99 : 175 81.
9. Sengupta S, Bhattacharya P, Duttagupta C. Association between HLA B*07 and human papillomavirus related cervical cancer in Indian women. In : Cancer Detection and Prevention. 7th International Symposium on Predictive Oncology & Intervention Strategies, February 7-10, Nice, France, 2004, S-106.
10. Laikangbam P, Sengupta S, Bhattacharya P et al. A comparative profile of the prevalence and age-distribution of human papillomavirus type 16/18 infections among three states of India with focus on Northeast India. Int J Gynecol Cancer 2007 : 17 : 107 17.
11. Miller SA, Dykes D, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988 : 16 : 1215.
12. Herrero R, Castle PE, Schiffman M et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005 : 191 : 1796 807.
13. Fontaine J, Gravitt P, Duh L-M et al. High level of correlation of human papillomavirus-16 DNA viral load estimates generated by three real-time PCR assays applied on genital specimens. Cancer Epidemiol Biomarkers Prev 2005 : 14 : 2200 7.
14. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. In : Furth M, Greaves MF, eds. Molecular Diagnostics of Human Cancer. New York : Cold Spring Harbor Laboratory Press, 1989, 209 14.
15. Haraf DJ, Nodzenski E, Brachman D et al. Human papillomavirus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 1996 : 2 : 755 62.
16. Duttagupta C, Sengupta S, Roy M et al. Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer: a screening strategy in the perspective of rural India. Eur J Cancer Prev 2002 : 11 : 447 56.
17. Bunce M, O'Neill CM, Barnado MCNM et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995 : 46 : 355 67.
18. Mehal WZ, Lo YM, Herrington CS et al. Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis. J Clin Pathol 1994 : 47 : 1077 81.
19. Yamashita T, Yaginuma Y, Saitoh Y et al. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis 1999 : 20 : 1733 6.
20. Davidson EJ, Davidson JA, Sterling JC, Baldwin PJ, Kitchener HC, Stern PL. Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res 2003 : 63 : 400 3.
21. Ellis JR, Keating PJ, Baird J et al. The association of an HPV16 oncogene variant with HLA B-7 has implications for vaccine design in cervical cancer. Nat Med 1995 : 1 : 464 70.
22. Georgopoulos NT, Proffitt JL, Blair GE. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 2000 : 19 : 4930 5.
23. O'Brien PM, Campo MS. Papillomaviruses: a correlation between immune evasion and oncogenicity? Trends Microbiol 2003 : 11 : 300 5.
24. Duggan-Keen MF, Keating PJ, Stevens FR et al. Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. Eur J Immunogenet 1996 : 23 : 275 84.
25. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild type p53 differ biochemically and biologically. Mol Cell Biol 1999 : 19 : 1092 100.
26. Dumont P, Leu JI, Della Pietra AC III., George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003 : 33 : 357 65.
27. 264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2004 : 10 : 6929 37.
28. Gnjatic S, Bressac-de P, Guillet JG, Choppin J. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur J Immunol 1995 : 25 : 1638 42.
29. Fujita H, Senju S, Yokomizo H et al. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol 1998 : 28 : 305 16.
30. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 1993 : 7 : 2565 74.
31. Marin M, Jost CA, Brooks LA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000 : 25 : 47 54.